lobbying_activities: 2969155

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2969155	c1ce83a0-27ad-4743-b01c-9943e0cbad33	Q1	WINNING STRATEGIES WASHINGTON	50796	KALEO	2023	first_quarter	PHA	Pharmaceutical drug development, including epinephrine for anaphylaxis; drug access and affordability issues	HOUSE OF REPRESENTATIVES,SENATE	30000		0	0	2023-04-19T13:01:45-04:00